Venus Remedies Limited – Transforming Critical Care with Research-Led Pharma Excellence

1. Venus Transforming Research-Led Pharma Excellence Remedies Limited Care – Critical with A 1,000‑Word Story of Innovation, Quality, and Global Reach Venus Remedies Limited, founded in 1989 and headquartered in Panchkula, Haryana, stands as a shining example of how a company can evolve from a generic pharmaceutical manufacturer into a globally recognized R&D-driven powerhouse. Today, Venus is known for its deep commitment to critical care injectables, antimicrobial resistance solutions, herbal and OTC wellness products, and oncology drugs—all backed by world-class scientific rigor and robust manufacturing processes ZaubaCorp+10LinkedIn+10Venus Remedies Limited+10. Roots & Geography: A Triple-Planted Footprint From its inception in Chandigarh region, Venus has steadily expanded its footprint: ● Indian Bases: Panchkula (head office), Baddi (state-of-the-art R&D center), and manufacturing facilities. ● European Manufacturing: A fully equipped facility in Werne, Germany. ● Global Reach: Marketing authorizations in over 90 countries, emphasizing a real global reach Venus Remedies LimitedLinkedIn. By integrating Indian agility with European compliance, Venus offers customers a unique combination: high-quality products, reliable supply chains, and recognized certifications like EU‑GMP and WHO‑GMP LinkedIn. R&D at the Core: VMRC, Patents, Innovation Here’s the thing: Venus isn’t just manufacturing drugs; it's creating new therapies. At the heart of that transformation lies the Venus Medicine Research Centre (VMRC), based in Baddi. Accredited by DSIR and GLP-compliant, VMRC breaks barriers with technologies like

2. hollow-fibre infection models and a human “organ-on-a-chip” kidney lab—first of its kind in India The Venus Times+1Venus Remedies Limited+1. A few key highlights: ● Over 100 patents, 70+ trademarks, and 12 copyrights The Venus Times. ● Industry-first organ-chip technology for preclinical safety and efficacy evaluations LinkedIn+7Venus Remedies Limited+7Venus Remedies Limited+7. ● Focused pipelines tackling antimicrobial resistance (AMR), oncology, pain management, neurology, skin and wound care—a mix of generics and new drug delivery formats Venus Remedies Limited. AMR isn’t a buzzword—it’s a crisis. Venus’s strategy? Deliver targeted solutions that preserve and enhance antibiotic effectiveness Venus Remedies Limited. Product Portfolio: Injectables, Critical Care, Herbal & OTC Let’s break it down: 1. Super‑Specialty Injectables & Critical Care Mercury‑class injectables like meropenem, imipenem-cilastatin, cefepime, oxaliplatin, gemcitabine, and bortezomib—many now approved in markets like Morocco—are trademarks of Venus’s strength in life-saving treatments Venus Remedies LimitedStockAnalysis+5Vivli AMR+5The Venus Times+5PharmaSource+2The Venus Times+2Vivli AMR+2. 2. Oncology & Antimicrobial Agents Products such as velimixin, vecaz, and cloti‑Xa underscore Venus’s leadership in anti-infectives and cancer care The Venus TimesVenus Remedies Limited. 3. Herbal & Consumer Health Solutions The company has made significant strides into the OTC segment, offering natural pain relievers (R3SET) and disinfectants (STERLOC), leveraging its research capabilities to tap into consumer wellness needs Venus Remedies Limited+1The Venus Times+1. 4. Vaccines, Antemetics, Cardiovasculars, Hormones Venus’s traditional strengths in antibiotics, analgesics, antipyretics, immunoagents, and respiratory products remain solid StockAnalysisCPHI Online.

3. Manufacturing & Certifications: Quality Meets Scale Venus has transformed over the years: ● Facilities: GMP-certified plants in India and Germany, full-scale CDMO/CMO services PharmaSource+1The Venus Times+1. ● Certifications: EU‑GMP, WHO‑GMP, Ukrainian SMDC certification—clear evidence of their global quality credentials Venus Remedies Limited+2Venus Remedies Limited+2LinkedIn+2. ● Annual Audits: Renewal and expansion of authorizations show consistent regulatory compliance Venus Remedies Limited. Financial Strength & Market Standing Venus is a publicly listed company (BSE/NSE: VENUSREM) with: ● Market Cap: Around ₹739 Crore; share price near ₹552 as of mid-July 2025 PharmaSource+4StockAnalysis+4The Economic Times+4. ● Revenue Profile: ₹201.7 Cr consolidated income in Q4 FY2025; ₹21 Cr net profit The Economic Times. ● Growth: Revenue climbed ~12.8% QoQ and ~1.3% YoY The Economic Times. ● Shareholding: Promoters hold 41.8%, FIIs 2.25% The Economic Times. ● Peers: Competes with Ind-Swift, Kilitch Drug, Zim Laboratories, Medicamen Bio based on financial comparables The Economic Times. Overall, it’s a lean, profitable SME with consistent execution and no heavy debt. Governance, Culture & Workforce Well‑Being The leadership team blends legal, operational, and R&D insights:

4. ● Key Management: Pawan Chaudhary (Chairman & MD), Manu Chaudhary (Jt MD), Ashutosh Jain (CEO), Peeyush & Akshansh Chaudhary in technical roles, plus a cross-functional board including independent Limited+2StockAnalysis+2The Economic Times+2. ● Employee Focus: Initiatives like Swachh Venus (hygiene), Pulse Connect (communication), work anniversaries, and family medical insurance show a progressive culture Venus Remedies Limited. ● Internal Events: Venus Pulse Connect (Nov 2024) fostered cross-department collaboration; internal newsletters StockAnalysis+5Venus Remedies Limited+5LinkedIn+5. directors Venus Remedies and awards maintained team spirit Vision, Sustainability & Future Focus Venus’s ‘Preserve the Core’ philosophy balances heritage manufacturing and bold innovation. From a legacy parenteral manufacturer to a custom R&D CDMO/CDMO+ player, they’ve charted a clear growth path The Venus Times. The annual report 2021–22 spells out goals like: ● Achieve ₹1,000 Cr turnover, global presence in 100+ countries. ● Sustain net debt-free operations. ● Expand people and R&D capabilities. ● Use clean energy and support sustainable practices Venus Remedies Limited. Their organ-on-a-chip and kidney-on-chip labs reflect how seriously they take next-gen pharma tech Venus Remedies Limited. Recent Milestones & Global Impact ● Ukraine GMP Renewal: Adds to export credibility Venus Remedies Limited. ● UNGC Membership: Signifies sustainability and ethics commitments Venus Remedies Limited.

5. ● CRITICARE 2025 (Kochi): Debuted products like Velimixin, Vecaz, Cloti‑Xa to over 1,500 global doctors Venus Remedies Limited. ● Morocco Medical Approvals: Global expansion of oncology and antimicrobial offerings The Venus Times. ● Employee Coverage: Launched comprehensive family medical insurance—showing internal care Venus Remedies Limited. Why Venus Matters ● Medical Impact: High-value injectables in areas like oncology, AMR, and critical care make real patient differences. ● Scientific Edge: Innovation-led tools like organ-on-chip position Venus ahead in pharma R&D. ● Affordability + Quality: Indian economy with German-grade manufacturing creates a competitive global offering. ● Global Footprint: Licensed in over 90 countries—a serious challenger among Indian mid-tier pharma players. Final Word Venus Remedies Limited is far from “just another pharmaceutical company.” It’s a story of transformation—one that balances legacy manufacturing, deep R&D, global compliance, and a people-first attitude. If you’re looking for a partner in critical care, oncology, AMR, herbal wellness, or CMO/CDMO needs—Venus delivers real value. Economically efficient, scientifically advanced, globally compliant, and ethically guided—they’re challenging the norms of how pharma is done, and that’s exactly what today's world needs.